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Summary
Avatrombopag, an oral thrombopoietin receptor agonist, was compared
with placebo in a 6-month, multicentre, randomised, double-blind,
parallel-group Phase 3 study, with an open-label extension phase, to assess
the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic
immune thrombocytopenia (ITP) and a platelet count <30 9 109/l (Clini-
calTrials.gov identifier NCT01438840). The primary endpoint was the
cumulative number of weeks of platelet response (platelet count
≥50 9 109/l) without rescue therapy for bleeding; secondary endpoints
included platelet response rate at day 8 and reductions in the use of con-
comitant medications. Amongst the 49 patients randomised, avatrombopag
(N = 32) was superior to placebo (N = 17) in the median cumulative
number of weeks of platelet response (124 vs. 00 weeks, respectively;
P < 00001). At day 8, a greater platelet response rate was also observed for
patients treated with avatrombopag compared with placebo (6563% vs.
00%; P < 00001), and use of concomitant ITP medications was also
reduced amongst patients receiving avatrombopag. The safety profile of
avatrombopag was consistent with Phase 2 studies; the most common
adverse events were headache and contusion. Overall, avatrombopag was
well tolerated and efficacious for the treatment of chronic ITP.
Keywords: bleeding disorders, thrombocytopenia, thrombopoietin, platelet
count, platelet disorders.
Current first-line treatments for chronic immune thrombocy-
topenia (ITP) include agents that decrease platelet destruc-
tion (e.g., corticosteroids, intravenous gamma globulin and
intravenous anti-RHo[D]) or suppress the production of
antiplatelet antibodies (e.g., immunosuppressants) (Provan
et al, 2010). However, these drugs have variable, transient
efficacy and significant toxicities, and relapse is common
upon discontinuation (Provan et al, 2003, 2010).
Two second-generation thrombopoietin (TPO) receptor
agonists, eltrombopag and romiplostim, have been approved
for the treatment of ITP in the United States and Europe.
Clinical guidelines recommend their use for patients with
ITP and a risk of severe bleeding who are not candidates for
splenectomy, and who have failed at least one other therapy
(Bussel et al, 2007; Kuter et al, 2008, 2010). Eltrombopag, a
small molecule TPO receptor agonist with a half-life of
~12 h, increases platelet counts after 8 days of daily oral
dosing, with levels returning to baseline 12 days after the last
dose (Jenkins et al, 2007). Romiplostim, a recombinant
fusion polypeptide administered weekly via subcutaneous
injection, increases platelet counts within 5 to 8 days, with
levels returning to baseline after 28 days (Wang et al, 2004).
Both TPO receptor agonists are generally well tolerated, with
the most common adverse event (AE) observed in 6-month
clinical studies being headache (Kuter et al, 2008; Cheng
et al, 2011). Eltrombopag, however, is associated with eleva-
tions in alanine aminotransferase and bilirubin, for which
it has a boxed warning for the risk of severe and poten-
tially life-threatening hepatotoxicity, and has important
restrictions relative to the timing of specific types of food
intake and drug administration (http://pi.amgen.com/united_
states/nplate/nplate_pi_hcp_english.pdf; https://www.pharma.
us.novartis.com/sites/www.pharma.us.novartis.com/files/promacta.
pdf). Both eltrombopag and romiplostim have also been
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associated with increases in thromboembolic events (Bussel
et al, 2009; Wong et al, 2017); for romiplostim, bone marrow
fibrosis has also been reported in some patients (Kuter et al,
2009; Ghanima et al, 2011).
Given the side-effect profiles and inconvenient dosing
requirements and/or route of administration of currently
available therapies, there remains an important unmet medi-
cal need for novel, orally administered TPO receptor ago-
nists, with improved safety and pharmacokinetic profiles for
the treatment of patients with chronic ITP.
Avatrombopag is a small molecule TPO receptor agonist
that mimics the biological effects of TPO in vitro and in vivo
(Fukushima-Shintani et al, 2008, 2009). In preclinical studies,
avatrombopag stimulated the proliferation of cultured
human c-Mpl–Ba/F3 cells and promoted the differentiation
of CD34+ cells from human cord blood to megakaryocytes in
a concentration-dependent manner (Fukushima-Shintani
et al, 2008, 2009). Notably, avatrombopag can be adminis-
tered orally with food, has no significant hepatotoxicity, and
avoids the safety and immunogenic risks of recombinant par-
enteral agents (Bussel et al, 2014). In Phase 2 studies, oral
avatrombopag increased platelet production in patients with
chronic ITP and was more effective than placebo in improv-
ing the platelet response rate on day 28 (Bussel et al, 2014).
Avatrombopag was generally well tolerated, with headache,
fatigue and epistaxis being the most frequently reported AEs
that occurred at exposure-adjusted incidence rates compara-
ble with placebo (Bussel et al, 2014).
The aim of the current Phase 3 study was to demonstrate
the superiority of avatrombopag to placebo in raising and
maintaining platelet counts in patients with chronic ITP
within a target range (50–150 9 109/l) over a 6-month treat-
ment period, and to assess the safety and efficacy of long-
term therapy with avatrombopag.
Methods
Study design
This Phase 3 multicentre, randomised, double-blind, parallel-
group, placebo-controlled study included a core study and
open-label extension phase, and evaluated the efficacy and
safety of oral avatrombopag versus placebo in patients with
chronic ITP (ClinicalTrials.gov identifier: NCT01438840).
The study was conducted at 27 study sites in Australia, Bel-
gium, Bulgaria, Czech Republic, New Zealand, The Nether-
lands, Poland, Singapore, Slovakia, South Africa and
Ukraine. Efficacy was evaluated over a 6-month treatment
period, and safety was assessed for up to 76 weeks following
completion of treatment. The concurrent use of other stan-
dard of care treatments for chronic ITP and rescue therapy
was allowed.
The protocol, informed consent form, and other docu-
ments were reviewed and approved by the sites’ Institutional
Review Board or Independent Ethics Committee. The study
was conducted in compliance with the International Confer-
ence on Harmonisation of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICH), and the
provisions of the Declaration of Helsinki, Good Clinical
Practice guidelines and local laws and regulations.
The study included the core study and the extension phase
(Fig 1). The pre-randomisation phase included a 4-week
screening period, and the core study consisted of baseline/
randomisation (day 1), titration (6 weeks), concomitant ITP
medication reduction period (12 weeks), maintenance
(8 weeks, including the end-of-treatment [EOT] visit), dose
tapering (4 weeks) and follow-up (4 weeks). Dose-tapering
and follow-up periods were only for patients who did not
continue into the extension phase. The extension phase
included a 6-week conversion period, a 90-week maintenance/
concomitant ITP medication reduction period, a dose-tapering
period and follow-up.
Patients
Eligible patients were males and females, ≥18 years of age,
with ITP ≥12 months in duration, and an average of two
platelet counts <30 9 109/l. Other inclusion criteria included
a peripheral blood smear consistent with ITP and previous
treatment with one or more therapies for ITP or patients
must have had a bone marrow examination consistent with
ITP within 3 years to rule out myelodysplastic syndrome or
other cause of thrombocytopenia. Key exclusion criteria
included secondary ITP, clinically significant arterial or
venous thrombosis, cardiovascular disease, chronic active
hepatitis, cirrhosis, gastric atrophy, malignant disease,
myelodysplastic syndrome, pernicious anaemia or portal
hypertension, and use of romiplostim or eltrombopag within
4 weeks of randomisation. All patients gave written informed
consent prior to screening.
Pre-randomisation phase
Screening visit and day 1 baseline/randomisation visit platelet
counts (obtained ≥48 h and ≤2 weeks apart) were averaged
to obtain the baseline platelet count prior to randomisation.
Randomisation and masking
Patients were centrally stratified by splenectomy status (yes
or no), baseline platelet count (≤15 9 109/l or >15 to
<30 9 109/l), and the use of concomitant ITP medication (yes
or no), and randomised using an interactive voice and web
response system to receive either avatrombopag or placebo
(2:1) in a double-blind fashion. During the randomisation
phase, patients and all personnel involved with the conduct
and interpretation of the study—including the investigators,
investigational site personnel and sponsor staff—were blinded
to the treatment codes (but not dose levels). Randomisation
data were kept strictly confidential, filed securely at each site,
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and were accessible only to authorised persons until the time
of unblinding. A master list of all treatments was maintained
in a sealed envelope with the sponsor. Corresponding patient
numbers associated with a specific treatment were blinded in
the interactive voice and web response system database. The
extension phase was not blinded.
Core study
The study drugs were packaged in a double-blind configura-
tion. Patients received therapy of either avatrombopag at a
starting dose of 20 mg or placebo, once-daily. The dose
could be titrated up to a maximum dose of 40 mg or down
to a minimum dose of 5 mg, according to pre-specified pro-
tocol thresholds and individual response to treatment. The
primary endpoint assessment was made during the
maintenance period of the core study, as concomitant ITP
medications were to be administered at a stable dose and
downward titration of the study medication was not permit-
ted during this period. The overall goal of the dose modifica-
tions was to maintain platelet counts ≥50 9 109/l and
≤150 9 109/l, and to reduce the need for concomitant ITP
medications.
Extension phase
Patients who completed the maintenance period of the core
study or discontinued from the core study early due to lack
of treatment effects, and who had no significant safety or tol-
erability concerns, were eligible to continue into the exten-
sion phase. All patients started the extension phase with
open-label avatrombopag 20 mg, once-daily. During the
Core study design
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Fig 1. Study design. (A) Core study. (B) Extension phase. AVA, avatrombopag; CONMED, concomitant medication; E, extension; EOT, end-of-
treatment; ITP, immune thrombocytopenia; PBO, placebo; qd, once-daily; R, randomised. *At EOT visit (visit 22), patients could enter the exten-
sion phase and receive open-label avatrombopag therapy. Patients who did not continue into the extension phase entered the dose-tapering and
follow-up phase. †Only for patients who did not enter the extension phase. ‡Optional entry into the open-label extension phase. §The screening
visit and day 1 baseline/randomisation visit platelet counts were averaged to obtain the baseline platelet count value. The two samples were
obtained ≥48 h and ≤2 weeks apart and the results were available prior to randomisation. Therefore, an additional screening platelet count may
have been required due to issues with scheduling. ‖Patients who discontinued early who met the criteria for a lack of treatment effect may have
moved directly into the open-label extension phase. [Colour figure can be viewed at wileyonlinelibrary.com]
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90-week maintenance period of the extension phase,
avatrombopag dose titration and downward titration of con-
comitant ITP medications were allowed. At the end of the
extension phase, a 4-week, dose-tapering period was followed
by a 30-day follow-up after the last dose of avatrombopag.
Concomitant therapy
Patients receiving concomitant ITP medication when enter-
ing the study were allowed to have this medication down-
titrated and ultimately eliminated during the concomitant
ITP medication reduction period of the core study and
during the maintenance period/concomitant ITP medication
reduction period of the extension phase. Down-titration of
concomitant ITP medication was implemented at the dis-
cretion of the investigator and could only be considered if
the patient’s platelet count remained >150 9 109/l. Patients
with a platelet count >150 9 109/l to ≤250 9 109/l could
have their concomitant ITP medication down-titrated by
≤25% of the original dose for 14 days, whereas the dose
was reduced by ≤50% in patients with a platelet count
>250 9 109/l for 14 days. If a patient was receiving ≥2 con-
comitant ITP medications, only one medication was down-
titrated at a time.
Study assessments
At each visit, platelet counts were measured and the use of
concomitant medication recorded to assess the use of any
rescue therapy. Rescue therapy (addition of any new ITP
medication) was administered at the discretion of the investi-
gators based on clinical assessment (e.g., due to life-threaten-
ing thrombocytopenia, a major bleeding event or signs/
symptoms of a potential bleeding event). The World Health
Organization (WHO) bleeding scale was used to assess the
incidence and severity of bleeding events, as previously
reported (Bussel et al, 2007; Kuter et al, 2008, 2010). Safety
was assessed by monitoring all treatment-emergent adverse
events (TEAEs) and serious adverse events (SAEs) through-
out the study. In addition, physical examinations, vital signs,
electrocardiograms (ECGs), blood chemistries, haematologies,
coagulation tests, a panel of gastric biomarkers and urine
analyses were regularly conducted. Bone marrow biopsies
were required during the study of patients who developed
immature or dysplastic cells on peripheral blood smear. In
addition, patients could elect to provide optional marrow
biopsies during the course of the study.
Lack of treatment effect was defined as platelet counts
<30 9 109/l after more than 3 weeks of treatment at the
maximum dose of 40 mg. Patients could be discontinued
from the core study if the investigator considered platelet
counts to be dangerously low after 7 days of treatment at the
maximum dose, if patients required rescue therapy more
than 3 times, or if they required continuous rescue therapy
for more than 3 weeks.
Efficacy endpoints
Core study. The primary efficacy endpoint was the cumula-
tive number of weeks of platelet response, defined as a plate-
let count ≥50 9 109/l in the absence of rescue therapy over
6 months of once-daily treatment in adults with ITP.
Secondary efficacy endpoints were the proportion of
patients with a platelet response at day 8 and the proportion of
patients with a reduction in the use of concomitant ITP medi-
cations from baseline. Exploratory efficacy endpoints included:
durable platelet response rate (defined as the proportion of
patients who had a platelet response for ≥6 of the last 8 weeks
of treatment), the incidence and severity of bleeding events, and
the proportion of patients receiving rescue therapy. The safety
of avatrombopag compared with placebo was also assessed.
Extension phase. In the extension phase, the efficacy and
safety of long-term avatrombopag therapy was assessed by
measuring platelet response rate, bleeding, and the use of res-
cue therapy.
Changes to efficacy endpoints. The study protocol was
amended in March 2013, changing the primary endpoint
from durable platelet response to the cumulative number of
weeks of platelet response over 6 months of treatment in
order to support a planned regulatory filing of avatrombopag
in Japan. Platelet response at day 8 was also changed from a
secondary to an exploratory endpoint, and the anticipated
sample size was reduced from 100 to 45 subjects.
Determination of sample size
A resampling method, based on results from a previous
4-week study that randomised 64 patients to placebo or ava-
trombopag (Bussel et al, 2014) was used to determine sample
size. The proportion of placebo- and avatrombopag-treated
patients with cumulative number of weeks of a platelet
response in that study were as follows: 0 weeks, 80% vs. 7%;
1 week, 20% vs. 0%; 2 weeks, 0% vs. 7%; 3 weeks, 0% vs. 7%;
and 4 weeks, 0% vs. 80%, respectively. It was assumed that a
similar treatment difference would be observed in the Phase 3
study with a longer treatment duration, and that there would
be a 15% dropout rate, with all dropout patients being con-
sidered to have 0 weeks of platelet response. A sample size of
45 patients (15 placebo, 30 avatrombopag) was projected to
provide at least 95% power to reject the null hypothesis of no
treatment difference between avatrombopag and placebo in
the cumulative number of weeks of platelet response during
the core study using the Wilcoxon rank sum test (a nonpara-
metric test) at a 005 significance level (2-sided).
Statistical analysis
The full analysis set (FAS) included all randomised patients,
and the safety analysis set (SAS) included all patients who
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received at least one dose of study medication and had a
post-dose safety assessment in either the core study or exten-
sion phase. All patients who received study medication and
who provided at least one platelet count and corresponding
efficacy assessment during the extension phase were included
in the modified full analysis set (mFAS). Baseline demo-
graphics and characteristics of the FAS and SAS were sum-
marised for each group using descriptive statistics and
categorical variables summarised by treatment group and by
frequency distribution.
Role of funding source
This study was funded by Eisai Inc. (Woodcliff Lake, NJ,
USA). The corresponding author had full access to all of the
data in the study and had final responsibility for the decision
to submit for publication.
Results
The study was conducted between 6 February 2012 and 9
April 2015. Of 100 screened patients, 49 met eligibility crite-
ria, were randomised to study medication (avatrombopag,
N = 32; placebo, N = 17), and were included in the FAS and
SAS. Twenty-two patients (688%) in the avatrombopag
treatment group and one (59%) in the placebo treatment
group completed the core study (Fig 2). The most frequent
reason for discontinuation from the core study was lack of
treatment effect (avatrombopag, N = 7; placebo, N = 15).
Thirty-nine patients who entered the extension phase were
included in the mFAS with 29 patients (744%) completing
the extension phase and nine (231%) discontinuing; one
patient was lost to follow-up.
Baseline demographics and characteristics were generally
balanced across the avatrombopag and placebo treatment
groups (Table I), except that there was a higher percentage
of avatrombopag-treated females (719%) compared with
placebo (471%; subsequent analysis suggested that the pri-
mary efficacy outcome was similar across male and female
subgroups). Most patients were in the low baseline platelet
count category (≤15 9 109/l; 571%), not splenectomised
(673%) and were not using concomitant ITP medication
(551%). Approximately 30% of patients had previously
received five or more ITP medications.
The duration of exposure for the core study was longer in
the avatrombopag treatment group, with 26/32 (813%)
patients receiving avatrombopag over 18 weeks, 17/32
(531%) over 26 weeks and 2/32 (63%) over 30 weeks.
(A)
(B)
Fig 2. Subject disposition. (A) Core study. (B) Extension phase. N/n, number of patients. [Colour figure can be viewed at wileyonlinelibrary.com]
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In the placebo treatment group, only 3/17 (176%) patients
were exposed to study medication over 18 weeks, and only
one was exposed to study medication for over 26 weeks.
Avatrombopag was shown to be superior to placebo in the
cumulative number of weeks of platelet response, the pri-
mary study endpoint, with a significantly longer duration of
a platelet count ≥50 9 109/l in the absence of rescue therapy
with avatrombopag than with placebo (median: 124 vs.
00 weeks; mean: 120 vs. 01 weeks; P < 00001). In addi-
tion, more patients in the avatrombopag treatment group
(21/32; 656%) had a platelet response at day 8 than in the
placebo-treated group (0/17; 00%; P < 00001; Table II).
Further, 5/15 (333%) patients in the avatrombopag treat-
ment group reduced their use of concomitant ITP medica-
tion from baseline compared with 0/7 placebo-treated
patients (333% vs. 0%, respectively; 95% confidence interval,
948, 5719) (Table II), although this treatment difference did
not reach statistical significance (N = 22; P = 01348) due to
the small number of patients using ITP medications at
baseline.
The durable platelet response rate was significantly greater
in avatrombopag-treated patients compared with those
receiving placebo (344% vs. 00%; P = 0009), with a treat-
ment difference of 344% (95% confidence interval, 1792,
5083). The median platelet count by visit in avatrombopag-
treated patients was consistently higher than that of the
placebo treatment group starting at day 8 (805 9 109/l vs.
8 9 109/l; Fig 3A), while the median platelet count for the
placebo treatment group remained unchanged throughout
the core study.
The overall platelet response rate observed in the core
study was generally maintained throughout the extension
phase until around week 36 (Fig 3B). Beyond week 38, plate-
let response was lower and more variable, but the small
number of patients (N < 15) at these time points limits fur-
ther interpretation.
The incidence of any bleeding event during the core study
was not statistically different between the avatrombopag and
placebo treatment groups (438% vs. 529%, respectively;
P = 05394), and was lower for avatrombopag when adjusted
for the 26-fold longer mean exposure time for avatrombopag-
treated patients. All bleeding events were WHO Grade 1,
except for three patients in the avatrombopag treatment group
who experienced Grade 2 (N = 2) or Grade 3 (N = 1) bleeding
events. The WHO Grade 3 bleeding event (epistaxis) was also
reported as an AE of special interest (AESI).
Although rescue therapy was required by 219% of
avatrombopag-treated patients and 118% of those who
received placebo, there was no statistically significant differ-
ence in the use of rescue therapy between these groups
(P = 04668 using Fisher’s exact test). The lower use of rescue
therapy by patients in the placebo treatment group is probably
artefactual due to the 26-fold shorter period of exposure in
placebo-treated individuals, resulting from the high rate of
early discontinuations due to lack of treatment effect.
As per International Working Group criteria, a complete
platelet response was defined as a platelet count ≥100 9 109/l
and an absence of bleeding (Rodeghiero et al, 2009). Simi-
larly, a platelet response was defined as a platelet count
≥30 9 109/l, with at least a two-fold increase in platelet
count from baseline and an absence of bleeding (Rodeghiero
et al, 2009). According to these criteria, 281% and 563% of
avatrombopag-treated patients achieved a complete platelet
response and platelet response, respectively, on day 8, com-
pared with 0% of those treated with placebo.
The mean duration of exposure to avatrombopag
(228 weeks) was approximately 26-fold longer than that of
placebo (89 weeks) in the core study, and the median,
Table I. Baseline demographics and patient characteristics (FAS).
Placebo (N = 17) Avatrombopag (N = 32) Total (N = 49)
Age (years), mean (SD) 412 (147) 464 (142) 446 (144)
<65 years, N (%) 16 (941) 29 (906) 45 (918)
Female, N (%) 8 (471) 23 (719) 31 (633)
Race, N (%)
White 15 (882) 31 (969) 46 (939)
Black or African American 1 (59) 0 1 (20)
Asian 1 (59) 1 (31) 2 (41)
Weight (kg), mean (SD) 8497 (2048) 8190 (2271) 8297 (2179)
Height (cm), mean (SD) 17053 (746) 16789 (800) 16881 (784)
BMI (kg/m2), mean (SD) 2924 (664) 2899 (732) 2908 (702)
Baseline platelet count, N (%)
≤15 9 109/l 10 (588) 18 (563) 28 (571)
15–30 9 109/l 7 (412) 13 (406) 20 (408)
≥30 9 109/l 0 1 (31) 1 (20)
Splenectomy, N (%) 5 (294) 11 (344) 16 (327)
Use of concomitant ITP medication at baseline, N (%) 7 (412) 15 (469) 22 (449)
BMI, body mass index; FAS, full analysis set; ITP, immune thrombocytopenia; N, number of patients; SD, standard deviation.
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(26.0 weeks and 6.0 weeks, respectively) 4.3 fold longer. In
the combined core study and extension phase, the mean
duration of exposure to avatrombopag was 439 weeks; the
longest exposure to avatrombopag was 757 weeks. Through-
out the core study and extension phase, 723% of patients
were exposed to avatrombopag for at least 32 weeks, and
298% received avatrombopag for at least 52 weeks.
Assessments of vital signs, ECGs, clinical laboratory evalu-
ations and a panel of gastric biomarkers identified no safety
signal.
While the overall incidence of TEAEs in the core study
was higher in the avatrombopag treatment group compared
with the placebo treatment group (969% vs. 588%, respec-
tively) (Table III), there were no clinically important differ-
ences in the exposure-adjusted incidence rates (43% per
patient-week vs. 66% per patient-week, respectively); the
higher overall incidence of TEAEs in avatrombopag-treated
patients was probably due to the greater mean (2.6 fold) and
median (4.3-fold) duration of exposure. Similarly, the over-
all incidence of SAEs in the core study was higher in the ava-
trombopag treatment group compared with placebo-treated
patients (281% vs. 59%), again, probably due to the
increased duration of exposure to avatrombopag. Impor-
tantly, nearly all SAEs in avatrombopag-treated patients
occurred in only single patients. Again, exposure-adjusted
incidence rates for SAEs were comparable in the core study
— 12% per patient-week and 07% per patient-week for the
avatrombopag and placebo treatment groups, respectively
(Table III).
The same pattern regarding overall incidence and exposure-
adjusted incidence rates was observed for treatment-related
TEAEs, Grade 3/4 AEs and TEAEs leading to study medication
dose adjustment (Table III). Four patients who received ava-
trombopag experienced Grade 3 TEAEs, which included single
SAEs of epistaxis, petechiae, headache and platelet count
reduction, which were considered related to study medication.
There were only two Grade 4 TEAEs in the core study; one
patient with a cerebrovascular accident who discontinued
study medication, and the other with worsening ITP that was
considered not related to study medication. There were no
deaths during the study in any treatment group. The expo-
sure-adjusted incidence rates for all TEAE categories were
comparable in the extension phase of the study.
The most commonly reported TEAEs in the avatrombopag
treatment group in the core study were headache, contusion,
upper respiratory tract infection, arthralgia, epistaxis, fatigue,
gingival bleeding and petechiae, with exposure-adjusted
incidence rates that were all comparable with, or lower than,
placebo (Table IV). The only additional TEAEs reported in the
open-label extension phase were a low incidence of thrombo-
cytopenia, hypertension, pharyngitis and nasopharyngitis. With
the exception of the two SAEs of vomiting and headache, which
were reported in two (63%) patients each, all other SAEs in
avatrombopag-treated patients in the core study occurred in
only individual patients (Table IV); no safety signal was identi-
fied. The only additional SAE reported in the extension phase
was thrombocytopenia/platelet count decreased.
AESIs were prospectively defined and collected, including
the recurrence of thrombocytopenia (defined as a platelet
count <10 9 109/l and >10 9 109/l below baseline), throm-
boembolic events, bleeding events (WHO Grade 3 or 4),
neoplastic events, gastric atrophy events, bone marrow
pathology and clinically significant liver tests. No AESIs were
reported in placebo-treated patients although the mean dura-
tion of treatment in this treatment group was very short
(89 weeks). No avatrombopag-treated patients had gastric
atrophy events or bone marrow pathology. One patient trea-
ted with 40 mg avatrombopag had an AE Grade 3 increase
in liver tests (according to the Common Terminology Crite-
ria for Adverse Events, v. 403; https://www.eortc.be/services/
doc/ctc/CTCAE_4·03_2010-06-14_QuickReference_5x7.pdf) in
the core study on day 82 that required no dose adjustment
or treatment, and returned to normal on continued
Table II. Summary of core study efficacy endpoints (FAS).
Placebo (N = 17) Avatrombopag (N = 32)
Cumulative number of weeks of platelet response*
Mean (SD) 01 (049) 120 (875)
Median 00 124
Min, max 0, 2 0, 25
P-value of Wilcoxon rank sum test <00001
Platelet count ≥50 9 109/l at day 8†
Yes (%, 95% CI) 00 (-,-) 656 (4917, 8208)
No (%) 1000 344
Difference of response rate (95% CI)‡ 6563 (4917, 8208)
P-value of Fisher’s exact test <00001
Reduction in use of concomitant ITP medications from baseline§
Placebo (N = 7) Avatrombopag (N = 15)
Yes (%, 95% CI) 00 (-,-) 333 (948, 5719)
No (%) 1000 667
Difference of rate of reduction
(95% CI)¶
3333 (948, 5719)
P-value of Fisher’s exact test 01348
CI, confidence interval; FAS, full analysis set; ITP, immune thrombo-
cytopenia; N, number of patients; SD, standard deviation.
*Cumulative number of weeks of platelet response is defined as the
total number of weeks in which platelet count is ≥50 9 109/l during
the core study in the absence of rescue therapy.
†Patients with platelet response (≥50 9 109/l) at day 8 in the
absence of rescue therapy on or before day 8.
‡Difference of response rate = platelet response rate at day 8 of ava-
trombopag – platelet response rate at day 8 of placebo, 95% CI is
calculated based on normal approximation.
§Only patients with use of concomitant ITP medications at baseline
were included in this analysis.
¶Difference of rate reduction = rate of reduction in use of concomi-
tant ITP medications from baseline of avatrombopag – rate of reduc-
tion in use of concomitant ITP medications from baseline of
placebo, 95% CI is calculated based on normal approximation.
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Fig 3. Median (Q1, Q3) platelet count over time. (A) Core study (FAS). (B) Extension phase (modified FAS). FAS, full analysis set; ITP, immune
thrombocytopenia; Med, medication; n, number of patients; Q1/3, quartile 1/3. [Colour figure can be viewed at wileyonlinelibrary.com]
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avatrombopag dosing; this patient had a history of fatty liver,
hepatitis C, obesity, gallstones and past liver function test ele-
vations, and reported the use of alcohol at the time the liver
function abnormalities developed. The investigator considered
this event unrelated to treatment with avatrombopag. Recur-
rence of thrombocytopenia, neoplastic events, and bleeding
events (epistaxis) were each reported in one avatrombopag-
treated patient (31%) over the 26-week core study. Three
patients (94%) reported a thromboembolic event in the core
study: a deep vein thrombosis (day 8), an asymptomatic pul-
monary embolism (day 154) and a cerebrovascular event (day
89). One additional thromboembolic event of jugular vein
thrombosis (day 335) was reported in the open-label exten-
sion phase. Of the four patients who reported thromboem-
bolic events, three had multiple risk factors for
thromboembolic disease and the reported events were associ-
ated with platelet counts from 39–271 9 109/l and were asso-
ciated with doses of avatrombopag ranging from 10 to
40 mg.
Discussion
Avatrombopag, a novel TPO receptor agonist currently under
development for the treatment of chronic ITP, demonstrated
efficacy and safety in Phase 2 studies (Bussel et al, 2014; Ter-
rault et al, 2014). These Phase 3 data confirm the safety and
efficacy of avatrombopag, which was shown to be superior to
placebo as measured by the cumulative number of weeks of
platelet response (platelet count ≥50 9 109/l) over 6 months
(26 weeks) of once-daily treatment in adult patients with
chronic ITP. Avatrombopag treatment resulted in a median
of 124 cumulative weeks of platelet response during the core
study and was also shown to be superior to placebo (0 weeks),
with a greater platelet response rate in avatrombopag-treated
patients at day (65.6 versus 0%, respectively).
Direct stimulation of the TPO signalling pathway to
increase platelet production with TPO receptor agonists has
proven efficacious in treating patients with chronic ITP (Bus-
sel et al, 2007; Kuter et al, 2008, 2010), supporting their use
as second-line therapies for patients unresponsive to initial
treatments (Wang et al, 2016). Efficacy data on the cumula-
tive number of weeks with a platelet count ≥50 9 109/l and
the durable platelet response have been reported for eltrom-
bopag and romiplostim (Cheng et al, 2011; Kuter et al, 2008;
http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.
pdf; Amgen Inc., 2017; https://www.pharma.us.novartis.com/
sites/www.pharma.us.novartis.com/files/promacta.pdf). How-
ever, some concerns remain over the long-term use of
TPO receptor agonists (Bussel et al, 2009; Kuter et al, 2009;
Ghanima et al, 2011; Wong et al, 2017).
In this Phase 3 study, avatrombopag was shown to be well
tolerated with a safety profile that was similar to placebo
Table III. Overview of TEAEs during the core study and extension phase (SAS).
Core study Core + extension phase
Incidence
Exposure-adjusted
incidence rate* Incidence
Exposure-adjusted
incidence rate*
Placebo
(N = 17)
N
(%)
Avatrombopag
(N = 32)
N
(%)
Placebo
(N = 17)
%
Avatrombopag
(N = 32)
%
Avatrombopag
(N = 47)
N
(%)
Avatrombopag
(N = 47)
%
TEAEs, N (%) 10 (588) 31 (969) 66 43 45 (957) 22
Treatment-related TEAEs†, N (%) 3 (176) 20 (625) 20 27 31 (660) 15
TEAE with CTCAE Grade 3 or 4, N (%) 0 6 (188) 0 08 14 (298) 07
SAEs, N (%) 1 (59) 9 (281) 07 12 15 (319) 07
Deaths 0 0 0 0 0 0
Other SAEs 1 (59) 9 (281) 07 12 15 (319) 07
TEAEs leading to study-drug
dose adjustment, N (%)
0 5 (156) 0 07 11 (234) 05
Withdrawal 0 3 (94) 0 04 6 (128) 03
Dose increase 0 1 (31) 0 01 3 (64) 01
Dose reduction 0 1 (31) 0 01 2 (43) 01
Dose interruption 0 0 0 0 0 0
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; N, number of patients; SAE, serious adverse event; SAS, safety
analysis set; TEAE, treatment-emergent adverse event. A TEAE (during core study) was defined as an AE that had an onset date (if not present
pre-treatment) or date of worsening in severity relative to pre-treatment state, on or after the first dose of study medication, up to 30 days after
the last dose of study medication during the core study (and before the first dose of extension phase if the patient continued into the extension
phase). For each row category, a patient with 2 or more AEs in that category was counted only once.
*Exposure-adjusted incidence rate = number of events/total patient-weeks exposure 9 100%.
†Includes TEAEs considered by the investigator to be possibly or probably related to study drug or TEAEs with missing causality.
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when adjusted for the duration of treatment exposure. Safety
findings were consistent with Phase 2 studies and with 6-
month studies with other TPO receptor agonists, with the
most frequently reported AE being headache (Bussel et al,
2007, 2014; Kuter et al, 2008, 2010; Cheng et al, 2011).
Although eltrombopag and romiplostim are generally consid-
ered to be well tolerated, eltrombopag has a boxed warning
for the risk of severe and potentially life-threatening hepato-
toxicity, requires routine monitoring of liver function and
has restrictions relative to dosing, while romiplostim must be
administered parenterally and may increase the risk for
development/progression of bone marrow reticulin fibre for-
mation. In contrast, avatrombopag can be administered
orally without regard to food type and, importantly, has not
been shown to be associated with significant hepatotoxicity.
There was a low incidence of AESI reported with avatrom-
bopag in the Phase 3 core study, with only one avatrombopag-
treated patient reporting a bleeding event (WHO Grade 3 or
higher) or recurrence of thrombocytopenia. The three throm-
boembolic events reported in the core study occurred in single
patients and were heterogeneous in nature (one deep vein
thrombosis, one pulmonary embolism and one cerebro-
vascular accident). However, the study population was not
large enough to rule out an increased incidence of thrombo-
embolic events with avatrombopag; this will need to be closely
monitored in ongoing and future studies.
These Phase 3 data extend the previously reported safety
and efficacy findings from prior Phase 2 studies (Bussel et al,
2014) and, taken together, support that long-term exposure to
avatrombopag is well tolerated and that once-daily oral treat-
ment is effective for the treatment of thrombocytopenia in
adult patients with chronic ITP. A US regulatory submission
for the approval of avatrombopag for the treatment of patients
with chronic ITP based on these data is planned in 2018.
Phase 3 studies are ongoing to evaluate the efficacy and safety
of avatrombopag in patients with thrombocytopenia sched-
uled for high-risk surgical procedures requiring platelet counts
of at least 100 9 109/l (NCT03326843), and patients with
ovarian, non-small cell lung and bladder cancer who develop
chemotherapy-induced thrombocytopenia (NCT03471078).
Study limitations
While this Phase 3 study demonstrated the superiority of
avatrombopag to placebo in the treatment of patients with
chronic ITP, its placebo-controlled design limits the
Table IV. Most frequent TEAEs and SAEs during core study and extension phase (SAS).
Core study Core + extension phase
Incidence
Exposure-adjusted
incidence rate*
Incidence
Exposure-adjusted
incidence rate*
Placebo
(N = 17) N (%)
Avatrombopag
(N = 32) N (%)
Placebo
(N = 17) %
Avatrombopag
(N = 32) %
Avatrombopag
(N = 47) N (%)
Avatrombopag
(N = 47) %
Any TEAE 10 (588) 31 (969) 66 43 45 (957) 22
Headache 2 (118) 12 (375) 13 16 14 (298) 07
Contusion 4 (235) 10 (313) 26 14 19 (404) 09
Upper respiratory tract infection 1 (59) 6 (188) 07 08 11 (234) 05
Arthralgia 0 (0) 4 (125) 0 05 5 (106) 02
Epistaxis 3 (176) 4 (125) 20 05 8 (170) 04
Fatigue 1 (59) 4 (125) 07 05 7 (149) 03
Gingival bleeding 0 (0) 4 (125) 0 05 8 (170) 04
Petechiae 1 (59) 4 (125) 07 05 7 (149) 03
Thrombocytopenia 0 (0) 2 (63) 0 03 9 (191) 04
Pharyngitis 1 (59) 0 (0) 07 0 6 (128) 03
Hypertension 1 (59) 2 (63) 07 03 5 (106) 02
Nasopharyngitis 0 (0) 3 (94) 0 04 5 (106) 02
Any SAE 1 (59) 9 (281) 07 12 15 (319) 07
Headache 0 (0) 2 (63) 0 03 2 (43) 01
Vomiting 0 2 (63) 0 03 2 (43) 01
Platelet count decreased 0 1 (31) 0 01 2 (43) 01
AE, adverse event; N, number of patients; SAE, serious adverse event; SAS, safety analysis set; TEAE, treatment-emergent adverse event.
A TEAE (during core study and extension phase) was defined as an AE that had an onset date (if not present pre-treatment) or date of worsening
in severity relative to pre-treatment state, on or after the first dose of study medication, up to 30 days after the last dose of study medication dur-
ing the core study and extension phase. A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threa-
tening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, or
caused a congenital anomaly/birth defect in the child of an exposed parent. Patients with ≥2 AEs in the same preferred terms was counted only
once for that preferred term.
*Exposure-adjusted incidence rate = number of events/total patient-weeks exposure 9 100%.
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conclusions regarding the relative efficacy of avatrombopag
compared with other approved TPO receptor agonists;
although the high statistical significance of both primary and
secondary endpoints (P < 00001) supports the robustness of
the effect of avatrombopag treatment in this patient popula-
tion. In addition, while 333% of patients in the avatrombopag
treatment group reduced their use of concomitant ITP medica-
tions compared with 0% of placebo-treated patients, the rela-
tively small number of patients using concomitant medication
at baseline is another potential limitation of this study. Another
limitation is the low cumulative exposure in the placebo treat-
ment group, due to a higher early discontinuation rate result-
ing from the lack of efficacy. The significantly higher mean
(2.6-fold) and median (4.3-fold) exposure duration in the
avatrombopag treatment group needs to be considered when
evaluating the safety results and limits their interpretation.
In conclusion, this Phase 3 study showed that avatrom-
bopag was superior to placebo in increasing platelet counts
in patients with chronic ITP over a 6-month treatment
period. Avatrombopag was generally well tolerated, with
exposure-adjusted incidence rates of TEAEs that were com-
parable with placebo, and a safety profile that was consistent
with that observed in Phase 2 avatrombopag studies and
studies of other TPO receptor agonists in patients with ITP.
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